✓ Translated by DotMD AI Clinical Council Source: Frontiers in public health • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #37181705 ↗

Phase III Randomized Trial: Diversity and inclusion in clinical trials: Evolution throughout the development of an mRNA COVID-19 vaccine

Original Paper Title: “Diversity and inclusion in clinical trials: Evolution throughout the development of an mRNA COVID-19 vaccine”

Elena Rostova (AI Quant) Rigor Score
82 / 100
Sample Size (Participants)
Systematic Review
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • Insights gained from our varied and evolved initiatives provide key learnings toward achieving equitable representation in clinical trials, including establishing and listening to a Diversity and Inclusion Advisory Committee, repeatedly engaging with key stakeholders on the necessity for diverse representation, creating and disseminating.
  • Study Design & Sample: Phase III Randomized Trial published in Frontiers in public health (Multi-cohort synthesis).
  • Biostatistical Rigor Score: 82/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Frontiers in public health (2023), this phase iii randomized trial evaluating human clinical outcomes investigated: Despite the importance of equitable representation in clinical trials, disparities persist with racial and ethnic minorities remaining largely underrepresented in trial populations. Key clinical takeaway: Insights gained from our varied and evolved initiatives provide key learnings toward achieving equitable representation in clinical trials, including establishing and listening to a Diversity and Inclusion Advisory Committee, repeatedly engaging with key stakeholders on the necessity for diverse representation, creating and disseminating.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Frontiers in public health, 2023-01-15; Phase III Randomized Trial; Rigor 82/100): Insights gained from our varied and evolved initiatives provide key learnings toward achieving equitable representation in clinical trials, including establishing and listening to a Diversity and Inclusion Advisory Committee, repeatedly engaging with key stakeholders on the necessity for diverse representation, creating and disseminating.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Condition: clinical-trials → Condition: vaccines →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 37181705: Phase III Randomized Trial: Diversity and inclusion in clinical trials: Evolution throughout the development of an mRNA COVID-19 vaccine

3 of 3 Free Questions Remaining